Severity of Hypertension Correlates with Risk of Thromboembolic Stroke

  • Hui PangEmail author
  • Bing Han
  • Qiang Fu
  • Qiumei Cao
Original Article


Hypertension plays a significant role in the development of atrial fibrillation (AF) and its complications. The coexistence of the two diseases increases the risk of thromboembolism events. Although CHADS2 and CHA2DS2-VASc scores have been used in the evaluation of the thromboembolism events in AF patients, the different levels of the blood pressure are not appropriately recognized. In this study, the 970 AF patients were divided into three groups according to the severity of hypertension. The CHADS2 and CHA2DS2-VASc scores in the patients of grade 3 hypertension were significantly higher than those of the patients with grade 1 and 2 hypertension, respectively (P < 0.05). Both the CHADS2 and CHA2DS2-VASc scores were positively related to the severity of hypertension (P < 0.001). Our data demonstrated that three grades for hypertensive subjects with AF significantly improved antithrombotic risk stratification in addition to current clinical risk stratification models, such as CHADS2 and CHA2DS2-VASc scores.


Atrial fibrillation Hypertension CHADS2 score CHA2DS2-VASc score 


Compliance with Ethical Standards

Sources of Funding

This research was supported by Jiangsu Provincial Medical Youth Talent (QNRC2016383) and Xuzhou Municipal Bureau of Science and Technology (KC16SH042).

Conflict of Interest

The authors declare that they have no competing interests.

Human Subjects/Informed Consent Statement

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration, as revised in 2000. Informed consent was obtained from all individual participants included in the study.

Animal Studies

No animal studies were carried out by the authors for this article.


  1. 1.
    Sterne, J. A., Bodalia, P. N., Bryden, P. A., Davies, P. A., López-López, J. A., Okoli, G. N., et al. (2017). Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technology Assessment, 21, 1–386.CrossRefGoogle Scholar
  2. 2.
    Henriksson, K. M., Farahmand, B., Åsberg, S., Edvardsson, N., & Terént, A. (2012). Comparison of cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke. International Journal of Stroke, 7, 276–281.CrossRefPubMedGoogle Scholar
  3. 3.
    Andersson, T., Magnuson, A., Bryngelsson, I. L., Frøbert, O., Henriksson, K. M., Edvardsson, N., et al. (2013). All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case-control study. European Heart Journal, 34, 1061–1067.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., et al. (2013). 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 34, 2159–2219.CrossRefPubMedGoogle Scholar
  5. 5.
    Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., et al. (2016). 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 18, 1609–1678.CrossRefPubMedGoogle Scholar
  6. 6.
    Vlachos, K., Letsas, K. P., Korantzopoulos, P., Liu, T., Georgopoulos, S., Bakalakos, A., et al. (2016). Prediction of atrial fibrillation development and progression: current perspectives. World Journal of Cardiology, 8, 267–276.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., et al. (2014). 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Journal of the American Medical Association, 311, 507–520.CrossRefPubMedGoogle Scholar
  8. 8.
    Ogunsua, A. A., Shaikh, A. Y., Ahmed, M., & McManus, D. D. (2015). Atrial fibrillation and hypertension: mechanistic, epidemiologic, and treatment parallels. Methodist DeBakey Cardiovascular Journal, 11, 228–234.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chen, P. S., Chen, L. S., Fishbein, M. C., Lin, S. F., & Nattel, S. (2014). Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circulation Research, 114, 1500–1515.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Greiser, M., Kerfant, B. G., Williams, G. S., Voigt, N., Harks, E., Dibb, K. M., et al. (2014). Tachycardia-induced silencing of subcellular Ca2+ signaling in atrial myocytes. The Journal of Clinical Investigation, 124, 4759–4772.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Venteclef, N., Guglielmi, V., Balse, E., Gaborit, B., Cotillard, A., Atassi, F., et al. (2015). Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. European Heart Journal, 36, 795–805a.CrossRefPubMedGoogle Scholar
  12. 12.
    Lim, H. S., Willoughby, S. R., Schultz, C., Gan, C., Alasady, M., Lau, D. H., et al. (2013). Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. Journal of the American College of Cardiology, 61, 852–860.CrossRefPubMedGoogle Scholar
  13. 13.
    Huisman, M. V., Rothman, K. J., Paquette, M., Teutsch, C., Diener, H. C., Dubner, S. J., et al. (2017). The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2. Journal of the American College of Cardiology, 69, 777–785.CrossRefPubMedGoogle Scholar
  14. 14.
    Camm, A. J., Lip, G. Y., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., et al. (2012). 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. European Heart Journal, 33, 2719–2747.CrossRefPubMedGoogle Scholar
  15. 15.
    January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland Jr., J. C., et al. (2014). 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology, 64, e1–76.CrossRefPubMedGoogle Scholar
  16. 16.
    Camm, A. J., Accetta, G., Ambrosio, G., Atar, D., Bassand, J. P., Berge, E., et al. (2017). Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart, 103, 307–314.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Cardiology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical CollegeAffiliated Xuzhou Hospital of Medical College of Southeast UniversityXuzhouChina

Personalised recommendations